title: Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics.
abstract: Neuroleptic treatment was instituted in 20 female schizophrenic patients, who had not received neuroleptics for at least the preceding 3 months. Both the therapeutic response to neuroleptics and the development of parkinsonian side effects were monitored in these patients. In addition, plasma dopamine-beta-hydroxylase (DBH) and platelet monoamine oxidase (MAO) activities were measured. None of the neuroleptic responders developed parkinsonian symptoms. During the course of the 28-day treatment, there was a significant decrease in platelet MAO activity. There was a tendency for responders without parkinsonian symptoms to have lower plasma DBH activity than did nonresponders with parkinsonian symptoms.
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D004299:Dopamine beta-Hydroxylase; D008995:Monoamine Oxidase